At a public hearing hosted by the FDA, stakeholders said the program needs clearer eligibility criteria and insight into how ...

Researchers are refining autologous tumor-infiltrating lymphocyte treatment while testing CAR T-cell therapies in new tumor ...

Adjuvant treatment with the drug reduced the risk of recurrence by 83 percent in patients with RET-positive tumors, data that ...

At ASCO, researchers reported that more patients who switched to camizestrant at molecular progression had total ctDNA ...

At ASCO, the company reported 9 partial responses during the dose-escalation phase of the study in neuroendocrine tumors.

Eli Lilly announced a deal to buy the Boston biotech Kelonia for up to $7 billion last month after early results made a ...

The draft guidance outlines how sponsors can use publicly available, internal company, and other existing knowledge as part ...

The recommendation is based on data showing that women lived an average of 16.9 months on the ADC compared to 13 months on chemo.

The firm is exploring a path forward for its gene-editing drug for chronic granulomatous disease, after saying last year it ...

As part of a research collaboration, the firms will develop AAV vectors for use in low-dose systemic gene therapies and in vivo CAR T-cell therapies.

Analysis of samples from the NATALEE trial, presented at ASCO, revealed some response-linked gene-expression patterns, but ...